Genotypic distribution of multidrug-resistant and extensively drug-resistant tuberculosis in northern Thailand
Authors Jaksuwan R, Tharavichikul P, Patumanond J, Chuchottaworn C, Chanwong S, Smithtikarn S, Settakorn J
Received 14 December 2016
Accepted for publication 16 March 2017
Published 10 June 2017 Volume 2017:10 Pages 167—174
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Suresh Antony
Risara Jaksuwan,1 Prasit Tharavichikul,2 Jayanton Patumanond,3 Charoen Chuchottaworn,4 Sakarin Chanwong,5 Saijai Smithtikarn,6 Jongkolnee Settakorn7
1Clinical Epidemiology Unit, 2Department of Microbiology, Faculty of Medicine, Chiang Mai University, Chiang Mai, 3Division of Clinical Epidemiology, Faculty of Medicine, Thammasat University, Pathum Thani, 4Division of Respiratory Medicine, Chest Disease Institute, Nonthaburi, 5Office of Disease Prevention and Control Region 10, Chiang Mai, 6Bureau of Tuberculosis, Department of Disease Control, Ministry of Public Health, Bangkok, 7Department of Pathology, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
Background: Multidrug/extensively drug-resistant tuberculosis (M/XDR-TB) is a major public health problem, and early detection is important for preventing its spread. This study aimed to demonstrate the distribution of genetic site mutation associated with drug resistance in M/XDR-TB in the northern Thai population.
Methods: Thirty-four clinical MTB isolates from M/XDR-TB patients in the upper northern region of Thailand, who had been identified for drug susceptibility using the indirect agar proportion method from 2005 to 2012, were examined for genetic site mutations of katG, inhA, and ahpC for isoniazid (INH) drug resistance and rpoB for rifampicin (RIF) drug resistance. The variables included the baseline characteristics of the resistant gene, genetic site mutations, and drug susceptibility test results.
Results: All 34 isolates resisted both INH and RIF. Thirty-two isolates (94.1%) showed a mutation of at least 1 codon for katG, inhA, and ahpC genes. Twenty-eight isolates (82.4%) had a mutation of at least 1 codon of rpoB gene. The katG, inhA, ahpC, and rpoB mutations were detected in 20 (58.7%), 27 (79.4%), 13 (38.2%), and 28 (82.3%) of 34 isolates. The 3 most common mutation codons were katG 315 (11/34, 35.3%), inhA 14 (11/34, 32.4%), and inhA 114 (11/34, 32.4%). For this population, the best genetic mutation test panels for INH resistance included 8 codons (katG 310, katG 340, katG 343, inhA 14, inhA 84, inhA 86, inhA 114, and ahpC 75), and for RIF resistance included 6 codons (rpoB 445, rpoB 450, rpoB 464, rpoB 490, rpoB 507, and rpoB 508) with a sensitivity of 94.1% and 82.4%, respectively.
Conclusion: The genetic mutation sites for drug resistance in M/XDR-TB are quite variable. The distribution of these mutations in a certain population must be studied before developing the specific mutation test panels for each area. The results of this study can be applied for further molecular M/XDR-TB diagnosis in the upper northern region of Thailand.
Keywords: tuberculosis, drug resistance, MDR-TB, XDR-TB, genotype, mutation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]